Top Markets
Coin of the day
Kazia Therapeutics Limited Kazia Therapeutics Limited

Kazia Therapeutics Limited

KZA
Rang in aandelen #35840
Kazia Therapeutics Limited is a biotechnology firm specializing in oncology,... Kazia Therapeutics Limited is a biotechnology firm specializing in oncology, committed to developing innovative therapies for cancer. Its flagship product candidate, Paxalisib, is a brain-penetrant small molecule that inhibits the PI3K/Akt/mTor pathway and is currently being investigated as a potential treatment for glioblastoma. Additionally, the company is progressing EVT801, an investigational new drug aimed at combating various types of cancer. Established in 1994 and headquartered in Sydney, Australia, the entity was formerly known as Novogen Limited before adopting the name Kazia Therapeutics Limited in November 2017.
Aandeelprijs
$0.05207079
Laatst gesynchroniseerd: 2023-11-15
Marktkapitalisatie
$3.38M
Verandering (1 dag)
0.13%
Verandering (1 jaar)
0.00%
Land
AU
Handel Kazia Therapeutics Limited (KZA)

Categorie

Dividendrendementgeschiedenis voor Kazia Therapeutics Limited (KZA)
Het dividendrendement (TTM) van Kazia Therapeutics Limited (aandelsymbool: KZA) per 2026 is: 0
Gemiddeld dividendrendement over de afgelopen 5 jaar: 0.00%
Dividendrendementgeschiedenis van Kazia Therapeutics Limited (KZA) van 2026 tot 2026
Dividendrendement aan het einde van elk jaar (TTM)
Jaar Dividendrendement Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Dividendrendementen (TTM) van vergelijkbare bedrijven of concurrenten